In terms of the primary outcome of reduction in A1C from baseline, although the 3-mg oral semaglutide group did not demonstrate superiority to sitagliptin 100 mg at 26 weeks, the 7-mg and 14-mg dosage groups did demonstrate statistically significant reductions in A1C from baseline when compared with sitagliptin
Nadolsky says that for some of his patients at the highest dose of tirzepatide, the drug is sometimes "dampening that dopamine reward system down so much that now, instead of just getting away from those addictive behaviors, they don't feel like doing anything." Some of those high-dose patients start seeking out sugar, not due to cravings, he says, but because their bodies are searching for some kind of stimulation to get the reward system going again
The question is not whether to eat carbs but which carbs and when
Factors that affect your results Your individual weight loss will depend on several factors beyond the medication itself
For example, a phase 2 trial showed that tirzepatide, a dual Gastric Inhibitory Polypeptide (GIP) and GLP-1 RA, significantly improved MASH
Additionally, eryptosis triggered by nanoscale materials can be associated with caspase-3 activation [452, 454] and calpain involvement [453, 458]
